Heart Test Laboratories, announced that on June 3 the Company received formal notice from the Listing Qualifications Staff of the Nasdaq Stock Market indicating that HeartSciences has regained compliance with bid price requirement as set forth in Listing Rule 5550(a)(2), and that the Company is therefore in compliance with the Nasdaq Capital Market’s listing requirements and the scheduled hearing has now been cancelled.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSCS:
- HeartSciences Regains Compliance with Nasdaq Listing Requirements
- HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
- Heart Test announces internationalization of its AI-ECG patent portfolio
- Heart Test Laboratories Inc trading halted, news pending
- HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG